Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 485Triple Negative Breast Neoplasms 28Carcinoma, Non-Small-Cell Lung 22Breast Neoplasms, Male 22Neoplasms 20Inflammatory Breast Neoplasms 20Neoplasm Metastasis 19Prostatic Neoplasms 17HER2-positive Breast Cancer 16Ovarian Neoplasms 13Lung Neoplasms 13Stomach Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Head and Neck Neoplasms 9Melanoma 8Esthesioneuroblastoma, Olfactory 8Carcinoma, Renal Cell 8Urinary Bladder Neoplasms 7Small Cell Lung Carcinoma 7Salivary Gland Neoplasms 7Pancreatic Neoplasms 7Esophageal Neoplasms 7Neutropenia 6Breast Diseases 6Sarcoma 5Carcinoma, Ovarian Epithelial 5Uterine Cervical Neoplasms 4Primary Breast Cancer 4Pathologic Complete Response 4Endometrial Neoplasms 4

Interventions

liposomal doxorubicin 1Vinorelbine 1Surveys and Questionnaires 1Prophylactic Mastectomy 1Docetaxel 1Cognitive Behavioral Therapy 1Cephalexin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genetic Predisposition to Disease × Docetaxel × Breast × Clear all
NCT03359694 2017-12-02

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 3 Unknown
300 enrolled
Breast

Breast Neoplasms, Genetic Predisposition to Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡